JP2014509515A5 - - Google Patents

Download PDF

Info

Publication number
JP2014509515A5
JP2014509515A5 JP2013558214A JP2013558214A JP2014509515A5 JP 2014509515 A5 JP2014509515 A5 JP 2014509515A5 JP 2013558214 A JP2013558214 A JP 2013558214A JP 2013558214 A JP2013558214 A JP 2013558214A JP 2014509515 A5 JP2014509515 A5 JP 2014509515A5
Authority
JP
Japan
Prior art keywords
biomarker
expression level
subject
breast cancer
eribulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013558214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014509515A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/029479 external-priority patent/WO2012129100A1/en
Publication of JP2014509515A publication Critical patent/JP2014509515A/ja
Publication of JP2014509515A5 publication Critical patent/JP2014509515A5/ja
Pending legal-status Critical Current

Links

JP2013558214A 2011-03-18 2012-03-16 エリブリンに対する応答を予測するための方法及び組成物 Pending JP2014509515A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161454426P 2011-03-18 2011-03-18
US61/454,426 2011-03-18
PCT/US2012/029479 WO2012129100A1 (en) 2011-03-18 2012-03-16 Methods and compositions for predicting response to eribulin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017046070A Division JP6612280B2 (ja) 2011-03-18 2017-03-10 エリブリンに対する応答を予測するための方法及び組成物

Publications (2)

Publication Number Publication Date
JP2014509515A JP2014509515A (ja) 2014-04-21
JP2014509515A5 true JP2014509515A5 (https=) 2015-04-23

Family

ID=45879070

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013558214A Pending JP2014509515A (ja) 2011-03-18 2012-03-16 エリブリンに対する応答を予測するための方法及び組成物
JP2017046070A Expired - Fee Related JP6612280B2 (ja) 2011-03-18 2017-03-10 エリブリンに対する応答を予測するための方法及び組成物
JP2019069638A Pending JP2019150027A (ja) 2011-03-18 2019-04-01 エリブリンに対する応答を予測するための方法及び組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017046070A Expired - Fee Related JP6612280B2 (ja) 2011-03-18 2017-03-10 エリブリンに対する応答を予測するための方法及び組成物
JP2019069638A Pending JP2019150027A (ja) 2011-03-18 2019-04-01 エリブリンに対する応答を予測するための方法及び組成物

Country Status (8)

Country Link
US (1) US9637795B2 (https=)
EP (1) EP2686441B1 (https=)
JP (3) JP2014509515A (https=)
CN (1) CN103562406B (https=)
CA (1) CA2828959A1 (https=)
ES (1) ES2731653T3 (https=)
SG (2) SG193489A1 (https=)
WO (1) WO2012129100A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102369008B (zh) 2009-03-30 2014-10-29 卫材R&D管理有限公司 脂质体组合物
RU2689977C2 (ru) * 2012-12-04 2019-05-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Применение эрибулина для лечения рака молочной железы
BR112015029386B1 (pt) * 2013-06-26 2023-11-14 Eisai R&D Management Co., Ltd. Uso de eribulina e lenvatinibe como terapia de combinação e kit
US20170100367A1 (en) * 2014-05-28 2017-04-13 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of cancer
WO2015184145A1 (en) * 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd. Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
AU2016226157B2 (en) * 2015-03-04 2022-01-27 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and eribulin for treating cancer
US10669545B2 (en) 2015-05-01 2020-06-02 Japan Science And Technology Agency Tumor cell malignant transformation suppressor and anti-tumor agent
PE20231050A1 (es) 2016-03-02 2023-07-11 Eisai Randd Man Co Ltd Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
WO2017188350A1 (ja) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
WO2019097073A1 (en) 2017-11-20 2019-05-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
WO2020179712A1 (en) * 2019-03-01 2020-09-10 Eisai R&D Management Co., Ltd. Methods for predicting tumor response to eribulin
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
CN113174427B (zh) * 2021-04-29 2023-02-28 遵义医科大学 基于DNA分子检测ERGIC3 mRNA的方法
CN113512733B (zh) * 2021-05-13 2022-07-26 浙江工业大学 一种电化学nhk反应合成艾日布林中间体的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5075216A (en) 1988-09-23 1991-12-24 Cetus Corporation Methods for dna sequencing with thermus aquaticus dna polymerase
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
CA2124087C (en) 1991-11-22 2002-10-01 James L. Winkler Combinatorial strategies for polymer synthesis
DE69433811T2 (de) 1993-01-07 2005-06-23 Sequenom, Inc., San Diego Dns - sequenzierung durch massenspektronomie
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
DE69829402T2 (de) 1997-10-31 2006-04-13 Affymetrix, Inc. (a Delaware Corp.), Santa Clara Expressionsprofile in adulten und fötalen organen
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
JP4454151B2 (ja) 1998-06-17 2010-04-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 大環状類似体及びそれらの使用並びに調製方法
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
WO2005032347A2 (en) * 2003-10-01 2005-04-14 The Ohio State University Research Foundation Determining the chemosensitivity of cells to cytotoxic agents
US20060154312A1 (en) * 2004-12-09 2006-07-13 Sergei Agoulnik Tubulin isotype screening in cancer therapy using halichondrin B analogs
TW201132813A (en) * 2010-03-03 2011-10-01 Koo Foundation Sun Yat Sen Cancer Ct Methods for classifying and treating breast cancers

Similar Documents

Publication Publication Date Title
JP2014509515A5 (https=)
JP2019150027A5 (https=)
JP6138154B2 (ja) 乳癌の予測および診断のためのバイオマーカー
JP2015517801A5 (https=)
US10408839B2 (en) Biomarker panel for diagnosing cancer
JP6401702B2 (ja) 炎症性肝疾患の診断のための方法および組成物
JP2012517241A5 (https=)
US20150160221A1 (en) Biomarkers for breast cancer predictions and diagnoses
JP2013500001A5 (https=)
JP2018504609A5 (https=)
JP2012507030A5 (https=)
WO2017039359A1 (ko) 트립토파닐 티알엔에이 합성효소를 이용한 감염 질환 또는 감염 합병증의 진단용 조성물과 진단 마커 검출 방법
JP6192122B2 (ja) 結腸直腸癌診断および予測のためのバイオマーカー
CN107255711A (zh) 骨桥蛋白用于制备或筛选慢加急性肝衰竭诊断试剂的用途
KR101297309B1 (ko) 폐암 진단용 조성물 및 폐암 진단키트
US20230133776A1 (en) Methods for diagnosing cancer
TWI598444B (zh) 用以評估乳癌罹患風險之方法及基因標記
WO2020179712A1 (en) Methods for predicting tumor response to eribulin
KR20130040294A (ko) 소세포폐암 진단용 조성물 및 소세포폐암 진단키트
JP2006525351A5 (https=)
CN113969312A (zh) 用于预测溃疡性结肠炎患者对戈利木单抗药物敏感性的标志物
JP2017529074A (ja) 治療剤に対する抵抗性の診断に使用するためのERCC1アイソフォーム3のmRNAおよび/またはタンパク質ならびにこのmRNAおよび/またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法
Goswami Understanding Cancer Through Biomarkers: Integrating Diagnostic Testing with Literature Analysis.
EP3701049A1 (en) Diagnosis and/or prognosis of her2-dependent cancer using moesin as a biomarker
KR20200045131A (ko) 장형 위암의 예후 진단 마커